Could Galena Biopharma, Inc. Be Running Out of Money?

Source: Galena Biopharma.

Galena's primary focus is to develop immunotherapy vaccines to fight cancer. These are vaccines which stimulate a cancer patients' immune system to better recognize and fight cancer cells. The company's most advanced immunotherapy candidate is NeuVax, which is currently being tested as an adjuvant therapy to prevent breast cancer recurrence in phase 3 studies (the PRESENT trial) with results due out at the end of 2016 or early 2017. In phase 2 studies in patients with low-to-moderate HER2 expression NeuVax resulted in a 78.4% reduction of cancer recurrence relative to the control group after five years.

In other words, NeuVax does have promise. But, does Galena have the resources to make it until early 2017?

Galena's cash position

As of the end of the second quarter Galena Biopharma had $39.2 million in cash and cash equivalents on hand with $10.1 million in debt, for a net cash position of $29.1 million. However, to provide context, this is down from $55.3 million in cash on hand as of March 14, 2014 as noted in the company's fourth-quarter report.

Where did $14.1 million in cash go over just a few months? Part of that cash went to fund the U.S. licensing rights to Zuplenz, a medication designed to treat chemotherapy-induced nausea and vomiting that Galena expects to launch early next year. The remaining cash was burned through by administrative and marketing expenses, as well as clinical trial costs. Keep in mind, the later stage a clinical trial is the more people it encompasses, and thus the more costly the trial becomes.

Though everything can depend on how tightly Galena controls costs, I'd estimate that Galena could be running out of money as soon as the end of 2015.

How Galena can boost its cash position

But, here's the good news: there are ways for Galena to raise capital and/or lower its rate of cash burn.

Source: Galena Biopharma.

One of the primary ways Galena has been looking to hedge its cash burn is through the acquisition of essentially pharmacy-shelf ready therapies. The acquisition of sublingual cancer pain medication Abstral from Orexo last year and the licensing of Zuplenz give Galena an opportunity to generate revenue now to help offset its administrative and clinical costs. Even though Abstral is looking as if it'll miss Galena's bullish projection of $11 million to $15 million in full-year revenue, combined Abstral and Zuplenz could deliver in the neighborhood of $20 million in total sales in 2015 and perhaps $30 million in 2016. From an EPS loss standpoint this could shrink Galena's net loss in half compared to Galena's full-year results prior to Abstral and Zuplenz.

Source: Galena Biopharma.

It's certainly possible that Galena could also license or partner NeuVax with a larger pharmaceutical company in order to raise cash. However, the prospect of this happening prior to Galena revealing its phase 3 PRESENT results are probably minimal at best. Adjuvant therapies and small-cap cancer drug developers haven't been the most successful combinations over the years, and will likely keep any potential licensing partners on the sidelines for at least two more years.

Finally, Galena can always turn to secondary share offerings in order to boost its cash on hand. This is the type of offering current shareholders loathe because it has the effect of diluting their existing shares. Between 2010 and the end of the second-quarter 2014 Galena's outstanding share count has risen from around 18 million to 118 million. Obviously, Galena's management team has had no qualms about selling its common stock to fund its operations and research and development costs. It's certainly something for current and prospective investors to keep their eyes on.

Could Galena be running out of money?

Now, let's return to, and answer, our original question: Could Galena Biopharma be running out of money?

In the most literal sense of the term I would indeed say that, as of right now, Galena probably doesn't have enough cash to get it through to late 2016 or early 2017 when it's scheduled to report the results of the PRESENT trial. For current investors it likely means Galena will turn to a stock offering once again in order to raise cash. Keep in mind the company does have $4.9 million under a revolving credit facility that it can use as well, but that won't get the company too far from an operations standpoint.

Its true valuation, however, depends on NeuVax. The PRESENT study truly holds make or break potential for this stock, with Abstral, Zuplenz, and even additional share offerings playing only a minor role. While I remain cautiously optimistic on Galena, I also am sticking squarely on the sidelines.

NeuVax could be a big seller for Galena, but this revolutionary new product has absolute game-changing potential!

The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .

The article Could Galena Biopharma, Inc. Be Running Out of Money? originally appeared on

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More